Nurix Therapeutics, Inc.

NasdaqGM NRIX

Nurix Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending August 31, 2024: 71.85%

Nurix Therapeutics, Inc. Gross Profit Margin is 71.85% for the Trailing 12 Months (TTM) ending August 31, 2024, a -11.46% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Nurix Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending August 31, 2023 was 81.15%, a 3.68% change year over year.
Nurix Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending August 31, 2022 was 78.27%, a 131.88% change year over year.
Nurix Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending August 31, 2021 was -245.52%, a 30.47% change year over year.
Nurix Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending August 31, 2020 was -353.11%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: NRIX

Nurix Therapeutics, Inc.

CEO	Dr. Arthur T. Sands M.D., Ph.D.
IPO Date	July 24, 2020
Location	United States
Headquarters	1700 Owens Street
Employees	284
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Key trends

Past 5 years